{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:59:38Z","timestamp":1791489578054,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":228,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CTRQQR-2021\\\\100010"],"award-info":[{"award-number":["CTRQQR-2021\\\\100010"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017008","name":"Cancer Research UK Manchester Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008719","name":"Movember Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008719","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101381","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:28:16Z","timestamp":1789673296000},"page":"101381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Radium-223 alters the levels of soluble immune regulators in the plasma of patients with metastatic castrate-resistant prostate cancer"],"prefix":"10.1016","volume":"49","author":[{"given":"Lunj","family":"S","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mistry","family":"H","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christodoulou","family":"T","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smith","family":"TAD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Y","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nightingale","family":"H","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patel","family":"K","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cutting","family":"P","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelthy","family":"M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greenhalgh","family":"M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reeves","family":"KJ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"West","family":"C","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoskin","family":"P","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honeychurch","family":"J","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choudhury","family":"A","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biolatti","family":"LV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101381_bib0001","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101381_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2018.06.004","article-title":"Real-world outcomes and factors predicting survival and completion of radium 223 in metastatic castrate-resistant prostate cancer","volume":"30","author":"Parikh","year":"2018","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101381_bib0003","article-title":"Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases","volume":"20","author":"Buscombe","year":"2021","journal-title":"World J. Nucl. Med."},{"key":"10.1016\/j.ctarc.2026.101381_bib0004","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.3390\/cancers15102784","article-title":"Assessing therapeutic response to radium-223 with an automated bone scan index among metastatic castration-resistant prostate cancer patients: data from patients in the J-RAP-BSI trial","volume":"15","author":"Kitajima","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2026.101381_bib0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1200\/JCO.2021.39.6_suppl.98","article-title":"Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer","volume":"39","author":"Choudhury","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101381_bib0006","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1158\/1078-0432.CCR-21-0063","article-title":"A Phase ib study of Atezolizumab with radium-223 dichloride in men with metastatic castration-resistant prostate cancer","volume":"27","author":"Fong","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101381_bib0007","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.3390\/diagnostics14212407","article-title":"Bone-targeting radionuclides in the treatment of metastatic castration-resistant prostate cancer: a review on radium-223 chloride (Alpharadin) in combination with other therapies","volume":"14","author":"Alshehri","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.ctarc.2026.101381_bib0008","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41585-024-00924-5","article-title":"Immune effects of \u03b1 and \u03b2 radionuclides in metastatic prostate cancer","volume":"21","author":"Lunj","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ctarc.2026.101381_bib0009","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-22-0306","article-title":"Randomized phase II study evaluating the addition of Pembrolizumab to radium-223 in metastatic","volume":"12","author":"Choudhury","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ctarc.2026.101381_bib0010","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/j.clgc.2017.10.010","article-title":"Immune analysis of radium-223 in patients with metastatic prostate cancer","volume":"16","author":"Kim","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.ctarc.2026.101381_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.667658","article-title":"Immunophenotyping reveals longitudinal changes in circulating immune cells during radium-223 therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Creemers","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2026.101381_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ctarc.2026.101381_bib0013","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.ctarc.2026.101381_bib0014","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s10147-024-02477-4","article-title":"MMP1, IL-1\u03b2, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors","volume":"29","author":"Nagasaka","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101381_bib0015","article-title":"Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications","volume":"12","author":"Chen","year":"2024","journal-title":"Biomarker"},{"key":"10.1016\/j.ctarc.2026.101381_bib0016","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13046-025-03293-y","article-title":"Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma","volume":"44","author":"Pourmir","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101381_bib0017","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1158\/1078-0432.CCR-22-0905","article-title":"Plasma CD27, a surrogate of the intratumoral CD27\u2013CD70 interaction, correlates with immunotherapy resistance in renal cell carcinoma","volume":"28","author":"Benhamouda","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101381_bib0018","article-title":"Biomarkers for predicting the efficacy of immune checkpoint inhibitors","volume":"13","author":"Wang","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101381_bib0019","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.3390\/ijms20081831","article-title":"Reduced T-cell numbers and elevated levels of immunomodulatory cytokines in metastatic prostate cancer patients de novo resistant to abiraterone and\/or enzalutamide therapy","volume":"20","author":"Pal","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2026.101381_bib0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41391-021-00412-6","article-title":"Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with radium-223","volume":"25","author":"Badrising","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.ctarc.2026.101381_bib0021","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e17034","article-title":"Predicting benefit of radium 223 based on biochemical response and site of metastasis: a real life multicenter UK study","volume":"39","author":"Das","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101381_bib0022","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1002\/cam4.5262","article-title":"Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: a real-world evidence multicenter study","volume":"12","author":"Hyv\u00e4kk\u00e4","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.ctarc.2026.101381_bib0023","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/annonc\/mdx044","article-title":"An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223","volume":"28","author":"Sartor","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101381_bib0024","doi-asserted-by":"crossref","first-page":"5604","DOI":"10.3390\/jcm12175604","article-title":"Prevalence and prognostic implications of PSA flares during radium-223 treatment among men with metastatic castration resistant prostate cancer","volume":"12","author":"Sidhu","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ctarc.2026.101381_bib0025","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-20-4476","article-title":"Randomized Phase II trial of Sipuleucel-T with or without Radium-223 in men with bone-metastatic castration-resistant prostate cancer","volume":"27","author":"Marshall","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101381_bib0026","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkad077","article-title":"Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response","volume":"7","author":"Parker","year":"2023","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.ctarc.2026.101381_bib0027","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/j.cllc.2021.04.007","article-title":"Bloodborne cytokines for predicting clinical benefits and immune-related adverse events in advanced non-small cell lung cancer treated with anti-programmed cell death 1 inhibitors","volume":"22","author":"Oyanagi","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101381_bib0028","article-title":"The ratio of IP10 to IL-8 in plasma reflects and predicts the response of patients with lung cancer to Anti-PD-1 immunotherapy combined with chemotherapy","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2026.101381_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008970","article-title":"Second-generation checkpoint inhibitors and treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment characterization","volume":"12","author":"Becker","year":"2024","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.ctarc.2026.101381_bib0030","first-page":"217","article-title":"Impact of checkpoint blockade on cancer vaccine\u2013activated CD8+ T cell responses","volume":"5","author":"Santos","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ctarc.2026.101381_bib0031","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40364-024-00647-0","article-title":"Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications","volume":"12","author":"Chen","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ctarc.2026.101381_bib0032","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/ijc.33610","article-title":"Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies","volume":"149","author":"Gorgulho","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101381_bib0033","article-title":"Calculation of radium\u2011223 and actinium-225 \u03b1\u2011emitter radiopharmaceuticals dose rates in treatment of metastatic castration\u2011resistant prostate cancer","author":"Abbasi","year":"2020","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.ctarc.2026.101381_bib0034","first-page":"103","article-title":"Radiosensitivity of prostate cancer cell lines for irradiation from beta particle-emitting radionuclide 177Lu compared to alpha particles and gamma rays","volume":"36","author":"Elgqvist","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ctarc.2026.101381_bib0035","article-title":"Radium-223 and actinium-225 \u03b1-emitter radiopharmaceuticals in treatment of metastatic castration-resistant prostate cancer","author":"Abbasi","year":"2021","journal-title":"Radiopharm. - Curr. Res. Better Diagn. Ther."},{"key":"10.1016\/j.ctarc.2026.101381_bib0036","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/annonc\/mdz270","article-title":"Advances in targeted alpha therapy for prostate cancer","volume":"30","author":"Vincentis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101381_bib0037","doi-asserted-by":"crossref","first-page":"86937","DOI":"10.18632\/oncotarget.13520","article-title":"Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas\u2019 sensitivity to lysis by antigen specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation","volume":"7","author":"Malamas","year":"2016","journal-title":"Oncotarget"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:36:18Z","timestamp":1791488178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":37,"alternative-id":["S2468294226002923"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101381","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radium-223 alters the levels of soluble immune regulators in the plasma of patients with metastatic castrate-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101381"}}